Mizuho Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Neutral with a price target of $130.00 (from $111.00).Analyst Irina ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE